PHARMALEADS___________
NAME OF THE CEOThierry BOURBIE
ADRESS11 rue Watt, 75013, Paris France
___________________
[email protected]
www.pharmaleads.com
MANAGEMENT TEAMCEO: Thierry BOURBIE
CFO: Pierre MaillardVP Medical Affairs, Strategy and BD: Michel
Wurm,
MD
TARGETEDMARKET
____________
Acute pain currently treated by injectable opiates
Chronic neuropathic/inflammatory pain
PRIVATE COMPANY
CREATION DATEDecember 2000
MISSIONP har m a l ead s d ev e l op s p r op r i e ta r y new
chem i ca l en t i t i es toa l l ev i a te s ev e r e p a i n ,
acu te o r ch r on i c , w i t hou t t he s i d e e f f ec t so f
op i a tes and o the r cu r r en t t r ea tm en ts . Our com p ound
s a r ei d ea l l y p os i t i oned to com b a t the op i o i d c r
i s i s , w h i ch cos t sb i l l i ons to the U n i t ed S ta tes
.
TECHNOLOGY
P har m a l ead s D E N KIs ( D ua l E nk ep ha l i nas e Inh i
b i t o r s ) i nh i b i tenk ép ha l i nas es , t he tw o enz y m
es w h i ch v e r y r ap i d l y d eg r ad eenk ep ha l i ns , t he
m a i n end og enous p a i n m od u l a to r s , t he r eb yi nc r
eas i ng the i r concen t r a t i ons and e l i c i t i ng l ong -
l as t i ngana l g es i c e f f ec t s , w i t hou t t he s i d e -
e f f ec t s o f ex og enous op i a tes .
COMPETITIONA cu t e p a in : i n j ec tab l e op i a tes
C h ro n ic p a in : g ab ap en t i no i d s and an t i d ep r
es s an t s
ALLIANCES/PARTNERSHIPS
A cad emic p ar t n ersh ip s :
• F l o r ence N ob l e , S a i n t s - P è r es M ed i ca l S
choo l , P a r i s 5
• Ra fae l M a l d onad o , U n i v e r s i t y P om p eu Fab r
a , Ba r ce l ona
• Rad houane D a l l e l , N eu r o - D o l I ns e r m U 1107 ,
C l e r m on t - Fe r r and
• E m i l y J u t k i ew i cz , U n i v e r s i t y o f M i ch i
g an
• S tep hane M e l i k - P a r s ad an i an t z , Annab e l l e
Réaux - Le Goaz i g o ,I ns t i t u t d e l a V i s i on , P a r i
s
• Ana Baam ond e , U n i v e r s i t y o f Ov i ed o
COMPANY SUMMARY
BIO Boston 1x1 meeting
COMPANY SUMMARY
BIO Boston 1x1 meeting
UPCOMING CATALYSTS
PL 265
Q3 2018 : I n i t i a t i on o f M u l t i p l e As cend i ng Or
a l d os es P has e 1s tud y
Q4 2018 : I n i t i a t i on o f 6 - w eek o r a l t ox s tud i
es i n tw o s p ec i es
Q3 2018: I n i t i a t i on o f 28 - d ay to l e r ab i l i t y
/P K s tud i es fo r ey e -d r op s
Q2 2019: Fo l l ow ed b y P has e 1 /2a c l i n i ca l s t ud y
fo r w i t h ey ed r op s ( ocu l a r p a i n )
PL 35 i . v .
Q4 2018 : I n i t i a t i on o f 2 - w eek i n fus i on tox s
tud i es i n tw os p ec i es
Q3 2019: Fo l l ow ed b y P has e 1 /2a c l i n i ca l s t ud y
( hea l t hyv o l un tee r s p l us p os t - s u r g i ca l p a i n
i n p a t i en t s a t t he end )
Pu b l ica t io n s
P ap er on e f f i cacy o f P L265 on ocu l a r p a i n and i n
f l am m at i ons ub m i t t ed to P a i n
Po st ersWIP , D ub l i n M ay 2018 , p r ec l i n i ca l r es u
l t s o f D E N KI
P a i n M echan i s m s and The r ap eu t i cs con fe r ence Tao
r m i na , J une2018 . Res u l t s o f op h tha l m o l og y s tud
i es w i t h P L265
IC OO 2018 , Bos ton , J une : l ack o f ad d i c t i v e p o
ten t i a l o f D E N KI
IAS P Bos ton , S ep tem b er 2018 : tw o p os te r s . E f f ec
t s o f P L37 onm i g r a i ne p a i n , p r ec l i n i ca l r es u
l t s o f D E N KI
PIPELINE
P has e 2 fo r P L37 and P L265 p l anned fo r 2019
PHARMALEADS___________
NAME OF THE CEOThierry BOURBIE
ADRESS11 rue Watt, 75013, Paris France
___________________
[email protected]
www.pharmaleads.com
MANAGEMENT TEAMCEO: Thierry BOURBIE
CFO: Pierre MaillardVP Medical Affairs, Strategy and BD: Michel
Wurm,
MD
TARGETEDMARKET
____________
Acute pain currently treated by injectable opiates
Chronic neuropathic/inflammatory pain
PRIVATE COMPANY
CREATION DATEDecember 2000
